Gestational diabetes mellitus screening and diagnosis: A prospective randomised controlled trial comparing costs of one-step and two-step methods

Division of Endocrinology and Metabolism, Department of Medicine and Obstetrics and Gynecology, Faculty of Medicine, McGill University Health Center, 687 Pine Avenue West, Montreal, QC, Canada.
BJOG An International Journal of Obstetrics & Gynaecology (Impact Factor: 3.86). 03/2010; 117(4):407-15. DOI: 10.1111/j.1471-0528.2009.02475.x
Source: PubMed

ABSTRACT To conduct a cost minimisation analysis of three methods of gestational diabetes mellitus (GDM) screening and diagnosis.
Prospective randomised controlled trial.
University teaching hospital.
Pregnant women (n = 1594) presenting for GDM screening.
Women presenting for GDM screening, who consented to participate, were randomised to GR1 [1-hour, 50-g glucose screen (GS) +/- 3-hour, 100-g oral glucose tolerance test (OGTT)], GR2 (50-g GS +/- 2-hour, 75-g OGTT) or GR3 (2-hour, 75-g OGTT). Demographics, health and time/travel cost information were assessed for each glucose testing visit.
Costs (direct and indirect) and prevalence of GDM diagnosis.
The direct sampling costs of the glucose tests per woman were as follows: GS, CAN$12.57; 75-g OGTT, $36.10; 100-g OGTT, CAN$48.13. Among women in the two-step method groups diagnosed with GDM, 39% of the GR1 and 61% of the GR2 groups were diagnosed at the first step by GS > or = 10.3 mmol/l, according to the Canadian Diabetes Association recommendations, contributing to a lower total cost in these groups. The total costs per woman screened were as follows: GR1, CAN$91.61; GR2, CAN$89.03; GR3, CAN$108.38. The GDM prevalence was similar (3.7%, 3.7% and 3.6%, respectively). The higher costs of GR3 were related to more blood draws and the time required for all women to undergo the 2-hour OGTT.
Careful consideration should be given to an internationally recommended method of universal screening for GDM which minimises the burden and cost for individual women and the healthcare system, yet provides diagnostic efficacy. The two-step method (GS +/- OGTT) accomplished this better than the one-step method (75-g OGTT).

Download full-text


Available from: Sara J Meltzer, Sep 15, 2014
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aims/hypothesis It is currently not clear how to construct a time- and cost-effective screening strategy for gestational diabetes mellitus (GDM). Thus, we elaborated a simple screening algorithm combining (1) fasting plasma glucose (FPG) measurement; and (2) a multivariable risk estimation model focused on individuals with normal FPG levels to decide if a further OGTT is indicated. Methods A total of 1,336 women were prospectively screened for several risk factors for GDM within a multicentre study conducted in Austria. Of 714 women (53.4%) who developed GDM using recent diagnostic guidelines, 461 were sufficiently screened with FPG. A risk prediction score was finally developed using data from the remaining 253 women with GDM and 622 healthy women. The screening algorithm was validated with a further 258 pregnant women. Results A risk estimation model including history of GDM, glycosuria, family history of diabetes, age, preconception dyslipidaemia and ethnic origin, in addition to FPG, was accurate for detecting GDM in participants with normal FPG. Including an FPG pretest, the receiver operating characteristic AUC of the screening algorithm was 0.90 (95% CI 0.88, 0.91). A cut-off value of 0.20 was able to differentiate between low and intermediate risk for GDM with a high sensitivity. Comparable results were seen with the validation cohort. Moreover, we demonstrated an independent association between values derived from the risk estimation and macrosomia in offspring (OR 3.03, 95% CI 1.79, 5.19, p < 0.001). Conclusions/interpretation This study demonstrates a new concept for accurate but cheap GDM screening. This approach should be further evaluated in different populations to ensure an optimised diagnostic algorithm.
    Diabetologia 09/2012; 55(12). DOI:10.1007/s00125-012-2726-7 · 6.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Schlüsselwörter Gestationsdiabetes, Insulinresistenz in der Schwangerschaft, diagnostische Kriterien, Insulintherapie Zusammenfassung Gestationsdiabetes (GDM) ist eine der häu-figsten Schwangerschaftserkrankungen mit steigender Prävalenz – nicht zuletzt wegen der bedenklichen Zunahme von Adipositas unter jungen Frauen. GDM ist aber auch eine der Schwangerschaftskomplikationen, über die in den letzten Jahren am meisten dis-kutiert wurde – mit den größten Kontroversen insbesondere zur Frage der Diagnostik. Auch die Ansichten über die Intensität der Stoff-wechselkontrolle, die Blutzuckerzielwerte und die Indikation zur Insulintherapie gingen weit auseinander, sehr zum Leidwesen der Be-handler und der Schwangeren. Die letzten fünf Jahre erbrachten durch die Veröffent-lichung bahnbrechender Studien einen gro-ßen Erkenntnisgewinn, der sich weltweit in neuen Empfehlungen zur Diagnostik und The-rapie des GDM niederschlägt. So auch in Deutschland: eine interdisziplinäre Arbeits-gruppe der Diabetologen, Geburtmediziner und Neonatalogen hat in Anlehnung an diese internationalen Empfehlungen die seit 2001 gültigen Leitlinien überarbeitet. Der nachfol-gende Artikel stellt die wichtigsten prakti-schen Aspekte für das diagnostische und the-rapeutische Vorgehen vor.
Show more